Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’re sending the newsletter a bit earlier today to get you some news out of federal court.

The need-to-know this morning

  • Novartis reported second-quarter earnings and reaffirmed its 2026 guidance. 
  • Agios Pharmaceuticals is discontinuing the development of a next-generation drug called tebapivat for sickle cell disease. A Phase 2 study did not establish a “differentiated profile to support continued development,” the company said.

Novo sues Lilly as GLP-1 fight escalates

Novo Nordisk this morning sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.

Continue to STAT+ to read the full story…